Global Noninvasive Cancer Diagnostics Market
Размер рынка в млрд долларов США
CAGR :
% 
USD
140.00 Billion
USD
244.17 Billion
2022
2030
 Прогнозируемый период |
2023 –2030 |
 Размер рынка (базовый год) |
USD 140.00 Billion |
 Размер рынка (прогнозируемый год) |
USD 244.17 Billion |
 CAGR |
% |
| Основные игроки рынка |
|
Global Non-Invasive Cancer Diagnostics Market, By Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other), Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis), Test Type (Urine Test, Imaging Test, Spectroscopy), Application (Blood, Urine, Saliva), End Users (Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others) - Industry Trends and Forecast to 2030.
Non-Invasive Cancer Diagnostics Market Analysis and Size
Cancer is one of the top causes of death globally, with a higher incidence in developed and developing markets. The rapid technological advancements in diagnostic tests are anticipated to accelerate industry growth as healthcare professionals focus on developing effective screening and treatment solutions to check prevalence levels. Numerous healthcare agencies and market players are launching different programs promoting different advanced diagnostics, thus accelerating market growth.
Data Bridge Market Research analyses the non-invasive cancer diagnostics market growth rate in 2023-2030. The expected CAGR of the non-invasive cancer diagnostics market is around 7.20% in the mentioned forecast period. The market was valued at USD 140 billion in 2022 and would grow to USD 244.17 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Non-Invasive Cancer Diagnostics Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Colorectal Cancer, Other), Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test (POCT), Hematology, Hemostasis), Test Type (Urine Test, Imaging Test, Spectroscopy), Application (Blood, Urine, Saliva), End Users (Hospital and Clinics, Diagnostic Centers, Ambulatory Care, Others) |
|
Countries Covered |
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Abbott. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Merck KGaA, (Germany), Hologic, Inc. (U.S.), BD. (U.S.), GSK plc. (U.K.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Pfizer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Non-invasive cancer diagnostics is a procedure to identify varied cancer problems with minimal body incision, such as cancer. The procedure usually consists of numerous techniques, such as identifying genetic structure, biomarker, molecular biology change, and imaging technologies. This process does not harm the body as it is non-invasive and allows no point or cut.
Non-Invasive Cancer Diagnostics Market Dynamics
Drivers
- Rising Developments of Diagnostic Testing Techniques
Technological advancements in diagnostic testing are anticipated to enhance market growth during the forecast period. For instance, in 2021, Hologic, Inc. announced commercial access to Europe's Genius Digital Diagnostics System. The next-generation cervical cancer screening system involves deep learning-based AI and innovative volumetric imaging technology, which helps to help detect cervical cancer cells and pre-cancerous lesions in women. Thus, this is expected to boost the market growth.
- Increasing Incidence of Cancer Cases
The rise in the number of cancer cases and the increase in the senior population are the major factors leading to the growth of the cancer diagnostics market worldwide. As per GLOBOCAN, 2020, around 19.3 million new cancer cases were reported worldwide, which is expected to reach 30.2 million new cases in 2040. Around 1 out of 6 deaths occur because of cancer worldwide, as per the World Health Organization factsheet. Around 70% of deaths from cancer occur in low- and middle-income countries. Thus, this boosts the market growth.
Opportunities
- Increasing Number of Awareness Programs by Major Organizations
An increasing number of initiatives to increase awareness about cancer screening in numerous organizations is a significant factor responsible for the increased demand for diagnostic products worldwide. In 2019, Fujifilm Medical Systems U.S.A. announced a new breast cancer screening awareness campaign that is primarily focused on early detection of the disease in the U.S. The ‘Aspire to Be Fearless’ campaign includes a mobile mammography vehicle traveling throughout the United States to raise Fujifilm’s message. Thus, this factor boosts the market growth.
- Growing Diagnostic Testing Kit Launches for Cancer
There has been a high number of testing kit launches that are assisting in the market growth. For instance, in 2020, Sysmex Corporation launched the ipsogen JAK2 DX reagent. It is a gene testing kit that evaluates the JAK2V617F mutation quantitatively, which is used for screening blood cancers. In addition, the product gained health insurance coverage, becoming Japan's first diagnostic product to be insured in 2020. Thus, this factor helps in the growth of the market.
Restraints/Challenges
- High Cost of Diagnostic Imaging
Several hospitals in underdeveloped and developing nations cannot invest in diagnostic imaging equipment due to high costs and budgetary constraints. However, due to the growing demand for diagnostic imaging in these countries, hospitals that cannot afford to purchase new and advanced imaging systems opt for rebuilt ones. Thus, this factor restraints the market growth.
This non-invasive cancer diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-invasive cancer diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Non-Invasive Cancer Diagnostics Market Scope
The non-invasive cancer diagnostics market is segmented based on type, product type, test type, application and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Lung Cancer
- Breast Cancer
- Solid Tumors
- Blood Cancer
- Ovarian Cancer
- Colorectal Cancer
- Other
Product Type
- Immunochemistry
- Clinical Microbiology
- Point of Care Test (POCT)
- Hematology
- Hemostasis
Test Type
- Urine Test
- Imaging Test
- Computerized Tomography
- Magnetic Resonance Imaging
- Nuclear Medicine Scans
- X-ray/Mammography
- Ultrasound
- Spectroscopy
Application
- Blood
- Urine
- Saliva
End Users
- Hospital and Clinics
- Diagnostic Centers
- Ambulatory care
- Others
Non-Invasive Cancer Diagnostics Market Regional Analysis/Insights
The non-invasive cancer diagnostics market is analyzed and market size insights and trends are on type, product type, test type, application and end users as referenced above.
The major countries covered in the non-invasive cancer diagnostics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the market because of the increasing presence of many biotechnology and medical device companies and growing funding for research and development projects. Also, this region's high adoption of advanced technologies boosts the market growth.
Asia-Pacific is projected to witness a massive growth in the market due to the growing incidence of cancer patients and awareness regarding minimal invasive equipment for diagnosis. Also, the growing government initiatives towards efficient healthcare diagnosis and better technology lead the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Non-Invasive Cancer Diagnostics Market Share Analysis
The non-invasive cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related non-invasive cancer diagnostics market.
Key players operating in the non-invasive cancer diagnostics market include:
- Abbott (U.S.)
- Thermo Fisher Scientific, Inc. (U.S.)
- Illumina, Inc. (U.S.)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Agilent Technologies, Inc. (U.S.)
- Quest Diagnostics Incorporated. (U.S.)
- Merck KGaA, (Germany)
- Hologic, Inc. (U.S.)
- BD. (U.S.)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Lilly. (U.S.)
- Pfizer, Inc. (U.S.)
- Myriad Genetics, Inc. (U.S.)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
